Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Director departure
Appointed director
Aceragen, Inc. (IDRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/18/2023 8-K Investor presentation
Docs: "2023 ACERAGEN 0 0.5 1 1.5 2 2.5"
09/28/2022 8-K Quarterly results
01/13/2021 8-K Quarterly results
01/15/2020 8-K Investor presentation
Docs: "Amendment to Employment Agreement, by and between the Company and Vincent J. Milano",
"Form of Vincent J. Milano Restricted Stock Unit Agreement",
"Investor Presentation"
10/31/2019 8-K Quarterly results
06/20/2019 8-K Investor presentation
Docs: "Investor Presentation"
01/07/2019 8-K Investor presentation
Docs: "Investor Presentation"
12/14/2018 8-K Investor presentation
Docs: "Investor Presentation",
"Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment - 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control - - Tumor shrinkage observed in both injected and uninjected lesions, indicating an abscopal effect -"
01/08/2018 8-K Investor presentation
Docs: "Investor presentation uploaded to Idera Pharmaceuticals, Inc. website on January 1, 2016"
05/22/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
03/07/2016 8-K Investor presentation
Docs: "Investor presentation uploaded to Idera Pharmaceuticals, Inc. website on March 7, 2016"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy